Sedation of Advanced Endoscopic Procedure
Effects of Target-controlled Infusion and Bispectral Index Monitoring in Sedation of Advanced Endoscopic Procedure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients undergo advanced endoscopic procedure
Exclusion Criteria:
- age less than 20 years, pregnant and lactating women, American Society of Anesthesiologists (ASA) class V, allergy to propofol, benzodiazepine, or opioid, and a requirement for general anesthesia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Target-control infusion without bispectral index monitoring
Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g.
endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
|
The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
|
|
Active Comparator: Target-control infusion with bispectral index monitoring
Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g.
endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
|
The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
propofol dose
Time Frame: during the endoscopic procedure
|
Total amount of propofol during the procedure
|
during the endoscopic procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sedation-related adverse events
Time Frame: during the endoscopic procedure
|
hypotension, hypoxemia
|
during the endoscopic procedure
|
|
Quality of sedation
Time Frame: 2 days
|
The satisfaction of the endoscopist with the sedation is evaluated by a case-by-case questionnaire.
Four classes of response: excellent, good, acceptable and poor, were defined for the overall evaluation with the safety of endoscopy procedure, patient cooperation and fluency of the procedure in the opinion of the endoscopist.
Patients' satisfaction includes their immediate evaluation of side effects such as post procedure dizziness, nausea/vomiting, or pain recall evaluation in the recovery room.
Telephone interviews are performed to ascertain the patients' overall satisfaction evaluation and of the procedure with four classes of responses: excellent, good, acceptable and poor.
|
2 days
|
|
Recovery: open eye, conscious clear, discharge time
Time Frame: within 2 hrs
|
Recovery data include time from end of endoscopy until eye opening on command and time from end of endoscopy until leaving the recovery room based on Aldrete score ≧ 9.
|
within 2 hrs
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: LIN, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 201612218RINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sedation
-
NCT07461376RecruitingPediatric Sedation | Clonidine Sedation | Ketamine Sedation
-
NCT02426320UnknownSedation | Mechanical Ventilation | Daily Sedative Interruption | Sedation Strategies | Sedation Protocols
-
NCT07336628CompletedProcedural Sedation | Conscious Sedation
-
NCT06389045CompletedSedation Complication | Procedural Sedation | Endoscopic Ultrasonography
-
NCT00641563CompletedCritical Care | Conscious Sedation | Deep Sedation
-
NCT07036419CompletedOperative Sedation of Pediatric | Operative Sedation of Adolescent Patients
-
NCT07239687RecruitingSedation | Target Controlled Infusion of Propofol | Intensive Care Unit Sedation
-
NCT05707884CompletedSedation Set-up Time | Additional Time Required for Volatile Sedation
-
NCT07219069Not yet recruiting
Clinical Trials on advanced endoscopic procedure
-
NCT04598256Completed
-
NCT00528775Terminated
-
NCT00505128Completed
-
NCT07594132Recruiting
-
NCT03724565CompletedEndoscopy, Gastrointestinal
-
NCT00987857UnknownEsophageal Cancer | Precancerous Condition
-
NCT01662024CompletedObesity | Overweight | Body Weight